Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

Some investors believe you make money when you buy a stock, not when you sell it ... provided there are good reasons to believe it will bounce back. CRISPR Therapeutics is a mid-stage biotech ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at $84.00. Discover outperforming stocks and invest smarter ...

That's because CRISPR Therapeutics soon will generate revenue from Casgevy, and this biotech also has a full pipeline of promising candidates based on the same gene-editing technology used in this ...

CRISPR's current valuation is attractive, with $1.9 billion in cash and expected revenue from Casgevy, making it a speculative but compelling buy. Editas and CRISPR are probably most closely ...